



March 27, 2020

Web Announcement 2150

Attention End Stage Renal Disease (ESRD) Facilities: Pharmaceuticals Included in Prospective Payment System (PPS)

The Centers for Medicare & Medicaid Services (CMS) publishes updates to the pharmaceuticals that are included in the Prospective Payment System (PPS) for End Stage Renal Disease (ESRD) Facilities. The following pharmaceuticals are included in the PPS rate effective on the dates indicated. Any Covered Outpatient Drugs (COD(s)) included in the PPS rate as documented in the CMS Manual System, Publication #100-04, Medicare Claims Processing, Transmittal 2134 will deny if billed separately.

Effective 1/1/15	
J3480	INJ. POTASSIUM CHLORIDE, PER 2 MEQ.
Effective 7/1/15	
J1439	INJ FERRIC CARBOXYMALTOSE, 1MG
Q9976	INJ. FERRIC PYROPHOSPHATE CIT
Effective 1/1/17	
J0620	CALCIUM GLYCER & LACT/10 ML
J0945	BROMPHENIRAMINE MALEATE
J3265	INJ TORSEMIDE
J7131	HYPERTONIC SALINE SOL
Effective 1/1/18	
J0604	CINACALCET, ORAL, 1 MG, (FOR ESRD ON DIALYSIS)
J0606	INJECTION, ETELCALCETIDE, 0.1 MG
J2360	INJECTION, ORPHENADRINE CITRATE, UP TO 60 MG
J7030	INFUSION, NORMAL SALINE SOLUTION , 1000 CC
J7042	5% DEXTROSE/NORMAL SALINE (500 ML = 1 UNIT)
J7060	5% DEXTROSE/WATER (500 ML = 1 UNIT)
J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC
Effective 1/1/19	
No Changes	
Effective 1/1/20	
No Changes	